To read the full story, subscribe or sign in.

Ardea Licenses MEK Inhibitors to Bayer in Deal Valued at $407M

April 29, 2009

Ardea Biosciences Inc. licensed its MEK inhibitors to Bayer Healthcare AG to develop potential treatments for cancer, in a deal worth up to $407 million. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 15, 2025.

Illimis $42M series B to spur study of Aβ-clearing fusion protein

BioWorld

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific...

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BioWorld

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...